Lymphoma (Bone Marrow Transplant): Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Basic Study Information

Purpose:
This study has two treatment groups: Group 1: For the first 6 days, you will get the usual chemotherapy (BEAM or CBV), plus the study drug ibrutinib. Then, you will receive ibrutinib for 12 months following AutoHCT. Group 2: For the first 6 days, you will get the usual chemotherapy (BEAM or CBV), plus a placebo (a pill that looks like the study drug but contains no medication). Then, you will receive a placebo for 12 months following AutoHCT. However, if you were to progress or relapse while taking the placebo, you would be offered treatment with the study drug, ibrutinib, at that time. The researchers want to know if adding ibrutinib to the usual chemotherapy given with AutoHCT could prevent your lymphoma from returning in the future. However, the addition of this medication could also cause side effects that the researchers want to know about.

Lead Researcher (Principal Investigator)

Lead Researcher: Michael Becker, MD

Study Contact Information

Additional Study Details

Return to Search